简介：AIMTo调查vasoactive的角色在形式剥夺的肠的肽(贵宾)近视(频分多路复用).METHODSFDM被放在三组八只小鸡创造一半透明在他们的右眼睛上更弥漫。Intravitreal注射盐并且贵宾一天被使用一次进组的堵塞眼睛2和3分别地。视网膜镜检法和轴的长度(AL)大小在第一和8th天更弥漫穿。在三个组的右眼睛和白天8上的第一个组的左眼睛的VIP受体和ZENK蛋白质的视网膜mRNA层次用在权利的中部的最后的折射(D)看的.RESULTSThe是的实时聚合酶链反应(PCR)被决定-13.75(-16.00,-12.00),-11.50(-12.50,-7.50),和-1.50(在组的-4.75,-0.75)1，2，和3，分别地(P<0.001)。在右眼睛的中部的AL(公里)是10.65(10.00，11.10)，9.90(9.70，10.00)，并且9.20(9.15，9.25)在组1，2，和3，分别地(P<0.001)。为VIP2受体的中部的三角洲三角洲周期阀值(CT)价值是1.07(0.82，1.43)，1.22(0.98，1.65)，0.29(0.22，0.45)在组的右眼睛1，2，和3，和1.18(0.90，1.37)在组1的左眼睛，分别地(P=0.001)。为ZENK蛋白质的中部的三角洲三角洲CT价值是1.07(0.63，5.03)，3.55(2.20，5.55)，在组的右眼睛无法发现1，2，和3和1.89(0.21，4.73)在组1的左眼睛，(P=0.001)分别地，.CONCLUSIONVIP在频分多路复用的发展有潜在的禁止的效果。

简介：AIM:Toevaluatetheefficacyandsafetyofacombinedtreatmentformyopicchoroidalneovascularization(CNV)usingphotodynamictherapy(PDT)andintravitrealbevacizumabandtocompareitwithintravitrealbevacizumabmonotherapy.METHODS:Thirty-foureyeswithangiographicevidenceofmyopicCNVwererandomlydividedintotwogroups:17weretreatedwithoneintravitrealbevacizumabinjection(1.25mg)andlow-fluence-ratePDTwithinsevendaysoftheinjection(GroupA).Theother17receivedmonotherapywithbevacizumabinjections(GroupB).Clinicalevidenceofcomplications,bestcorrectedvisualacuity(BCVA)andfluoresceinleakagewereevaluated.BCVAandopticalcoherencetomography(OCT)wereevaluatedmonthly.Thetimepointsfollow-upwasestablishedat6and12mo.AllpatientswereretreatedfollowingaPRNprotocol.RESULTS:Atotalof34eyesof34patients(26womenand8men)withameanageof62.35yearswereincluded.InGroupA(17eyes)themeanBCVAincreasedfrom0.55±0.13logMARbeforethetreatmentto0.40±0.09logMARatthe12mofollow-up(P<0.01).InGroupB(17eyes)themeanBCVAincreasedfrom0.60±0.11logMARbeforethetreatmentto0.55±0.12logMARatthe12mofollow-up(P<0.01).TherewasnostatisticallysignificantdifferencebetweenthetwogroupsintermsofLogMarvisualacuity.InGroupAthemeannumberofcombinedtreatmentswas1.8±0.11perpatient;inGroupBthemeannumberofintravitrealbevacizumabinjectionswas3.1±0.08perpatient.ThenumberoftreatmentswassignificantlyfewerinGroupA(P<0.01).Nolocalorsystemicsideeffectsoccurredamonganyofthepatientstreatedinthisstudy.CONCLUSION:Thecombinationofanti-angiogenicinjectionsandPDTappearstobeasafeandeffectiveoptionformyopicCNVtreatmentandallowsforasignificantreductionofintravitrealinjections.

简介：DearEditor,IamDr.KhayWeiPohfromDepartmentofOphthalmology,HospitalKualaLumpur,Malaysia.IwritetoshareacaseofdiffusechoroidalhaemangiomainachildwithSturgerWebersyndromewhoshowedresolutionofexudativeretinal

简介：AIM:Toestablishtheratmodelofstreptozotocin(STZ)induceddiabeticretinopathy(DR),whichisthemostcommoncauseofvisuallossandblindnessinpatientswithdiabetes,andobservethegeneexpressionofvascularendothelialgrowthfactor(VEGF)anditsreceptorsduringthedevelopmentofDR.METHODS:AratmodelofdiabeteswasestablishedbyintraperitonealinjectionofSTZ.Thediabeticratswerehousedfor2,3and4monthsafterthedevelopmentofdiabetes.Retinalhistopathologicalobservationwasperformed.TheretinalvesselswereobservedbyimmunofluorescencestainingbyCD31.ThemRNAexpressionofVEGF,VEGFreceptor1and2(VEGFR1/2)inratretinawasdetectedbyreversetranscriptionpolymerasechainreaction(RT-PCR)analysis.RESULTS:Retinalhistopathologicalobservationshowedthemorphologicalchangesofinnernuclearlayer(INL)andouternuclearlayer(ONL)atanytime-point,andalsodemonstratedtheincreasednewvesselsatboth3,4monthsafterthedevelopmentofdiabetes.TheCD31stainingresultsshowedthatthenumberofvesselswasincreasedintheretinasofdiabeticratsatboth3and4monthsafterthedevelopmentofdiabetes.Ascomparedtothenormalrats,themRNAexpressionofVEGFwasincreasedinretinasofdiabeticratsat3monthsafterthedevelopmentofdiabetes,whileVEGFR1andVEGFR2mRNAexpressionwasincreasedat2,3and4monthsafterthedevelopmentofdiabetes.CONCLUSION:Takentogether,ourresultsdemonstratedthatDRwasoccurredat3monthsafterthedevelopmentofdiabetes,andthemRNAexpressionofVEGF,VEGFR1andVEGFR2wereincreasedintheprocessofDR.ThepresentstudyfurtherevidencedtheinvolvementofVEGFanditsreceptorsintheprocessofDR.

简介：

简介：Leber'scongenitalamaurosis(LCA)andrecentgenetherapyadvancementfortreatinginheritedretinopathieswereextensiveliteraturereviewedusingMEDLINE,PubMedandEMBASE.Adeno-associatedviralvectorswerethemostutilisedvectorsforoculargenetherapy.Conephotoreceptorcellsmightuseanalternatepathwaywhichwasnotreliantoftheretinalpigmentepithelium(RPE)derivedretinoidisomerohydrolase(RPE65)toaccessthe11-cisretinaldehydechromophore.Researcheffortsdedicatedontheprogressionofagene-basedtherapyforthetreatmentofLCA2.Suchgenetherapyapproacheswereextremelysuccessfulincanine,porcineandrodentLCA2models.TherecombinantAAV2.hRPE65v2adenoassociatedvectorcontainedtheRPE65cDNAandwasreplicationdeficient.ItsinvitroinjectionintargetcellsinducedRPE65proteinproduction.Thegenetherapytrialsthatweresofarconductedforinheritedretinopathieshavegeneratedpromisingresults.PhaseIclinicaltrialstocureLCAandchoroideremiademonstratedthatadeno-associatedviralvectorscontainingRPEgenesandphotoreceptorsrespectively,couldbesuccessfullyadministeredtoinheritedretinopathypatients.AphaseIIItrialispresentlyongoingandifsuccessful,itwillleadthewaytoadditionalgenetherapyattemptstocuremonogenic,inheritedretinopathies.

简介：为了在长期的绿内障patients.METHODSA评估有中央角膜的subbasal神经纤维层的眼睛的表面变化和它的关联，没有任何眼睛的问题，眼睛的表面评估的未来的比较学习为至少6mo和25个正常题目的50只眼睛在使用二的25个病人或更多的antiglaucoma药的50只眼睛被执行作为控制。评估的学习参数包括了视觉尖酸，intraocular压力，眼睛的表面评估参数[荧光黄分散时间(FTBUT)，我测试的Schirmers，眼睛的表面染色分数和眼睛的表面疾病索引分数(OSDI)]，中央角膜的感觉(CochetBonnettaesthesiometer)，由在绿内障盒子和控制组中的共焦的microscopy.RESULTSThe平均数值的中央subbasal神经纤维层密度(SBNFLD)分别地如下：OSDI分数(35.89祣潴楫敮????????????木????€???€乔????偉?‰??????????倨???‵？？

简介：AIMTo与医学上在开的角度绿内障(OAG)或在医药treatment.METHODSThis学习是的antiglaucoma下面是主要或第二等的OAG病人的回顾的评论的眼睛的高血压(OHT)病人和OHT病人作为附属治疗估计有图案的激光trabeculoplasty(PLT)的功效和安全不受管束(18公里Hg)intraocular压力(IOP)谁经历了360浥湡？

简介：AIM:Toevaluatethelong-termresponsetothefixedcombinationofdorzolamide/timololinpatientswithprimaryopenangleglaucoma(POAG)andtheadditionofotherintraocularpressure(IOP)loweringmedicationssuchasprostaglandinanalogsandbrimonidine.METHODS:Aretrospective,non-randomized,anddescriptiveclinicalstudywasperformedwith182eyesdiagnosedwithPOAG.Patientsweredividedintothreegroups:agroupwithfixedcombinationofdorzolamide/timololonly,asecondgroupwithprostaglandinanalogsplusfixedcombinationofdorzolamide/timolol,andathirdgroupwiththeadditionofbrimonidinetothesamefixedcombination.IOPdataweregatheredretrospectivelyandthedifferencesbetweengroupswerecalculated.RESULTS:IOPwasreducedsatisfactorilyinallthreegroups;however,aprogressiveIOPreductionwasnotedinthegroupwiththefixedcombinationplusprostaglandinanalogs.Inthisgroup,aprogressive,significantandmorehomogeneousresponseofthereductionwasnotedincomparisonwiththeothergroups.CONCLUSION:IOPreductionwasefficaciousinallthreegroups.TheadditionofprostaglandinanalogsshowedprogressiveIOPreduction,progressiveresponseandabsenceoflong-termdrift.Brimonidinedidnotshowasignificantadditiveeffect.

简介：AIM:Toevaluatetheefficacyandsafetyofanti-vascularendothelialgrowthfactor(VEGF)combinedwithphotodynamictherapy(PDT)versusanti-VEGFmonotherapyforpolypoidalchoroidalvasculopathy(PCV).METHODS:WeconductedaMeta-analysisof9studiestocomparetheefficacyandsafetybetweencombinedtherapyandanti-VEGFmonotherapyforPCV.TheprogramsofRevMan5.3andStata12.0wereusedtoanalyzedata.RESULTS:Thebestcorrectedvisualacuity(BCVA)incombinedtherapygroupweresignificantlybetterthanthoseofanti-VEGFmonotherapygroupat6,24and36mo,withpooledweightedmeansdifferences(WMDs)of0.12(0.06,0.18),0.25(0.12,0.38)and0.28(0.13,0.43),respectively.Thecentralretinalthickness(CRT)reductionsincombinedtherapygroupwerehigherthanthatinantiVEGFmonotherapygroupat1,3,6and9mo,withpooledWMDsof63.90(20.41,107.38),33.47(4.69,62.24),30.57(0.12,60.01)and28.00(2.51,53.49),respectively.Theregressionrateofpolypsincombinedtherapygroupwasmuchhigherthanthatinanti-VEGFmonotherapygroup[RD:0.47(0.26,0.68);P<0.0001].Theadverseeventretinalhemorrhagedidnotdiffersignificantlybetweenthetwogroups.CONCLUSION:OurfindingsclearlydocumentthatantiVEGFcombinedwithPDTisamoreeffectivetherapyforPCVcomparedwithanti-VEGFmonotherapy.Furthermore,combinedtherapydoesnotincreasetheincidenceofretinalhemorrhage.

简介：

简介：AIMTo评估联合反脉管的endothelial生长的功效和安全因素(VEGF)代理人，口头的glucocorticoid，和为有斑点的浮肿的激光光致疑结治疗(我)对.METHODSThis学习包括了的网膜的静脉吸藏(RVO)第二等16个病人与的16只眼睛联系RVO我。病人们开始与口头的泼尼松和一个intravitrealanti-VEGF代理人被对待。二个星期以后，病人们经历了标准激光光致疑结。改正最好的视觉尖酸(BCVA)，中央网膜的厚度(CRT)，和网膜的容器氧化在收到的12mo.RESULTSPatients上被检验1.43

简介：AIM:Tocomparetheefficacyandsafetyofcombinationofranibizumabwithphotodynamictherapy(PDT)vsranibizumabmonotherapyinthetreatmentofage-relatedmaculardegeneration(AMD).METHODS:TheCochraneCentralRegisterofControlledTrials(CENTRAL)intheCochraneLibrary,Pubmed,andEmbaseweresearched.Therewerenolanguageordatarestrictionsinthesearchfortrials.Onlyrandomizedcontrolledtrials(RCTs)wereincluded.MethodologicalqualityoftheliteratureswasevaluatedaccordingtotheJadadScore.RevMan5.2.6softwarewasusedtodothemeta-analysis.RESULTS:Sevenstudieswereincludedinoursystematicreview,amongwhichfourofthemwereincludedinquantitativeanalysis.Theresultshowsthattheranibizumabmonotherapygrouphadabettermeanbestcorrectedvisualacuity(BCVA)changevsbaselineatmonth12comparedwiththatofthecombinationtreatmentgroup,andthestatisticaldifferencewassignificant(WMD,-2.61;95%CI,-5.08to-0.13;P=0.04).However,aftertheremovalofonestudy,thedifferencebetweenthetwogroupsshowednosignificantdifference(WMD,-2.29;95%CI,-4.81to0.23;P=0.07).Meanwhile,nosignificantcentralretinalthickness(CRT)reductionwasfoundinthecombinationtreatmentgroupandtheranibizumabmonotherapygroupat12monthsfollow-up.Nevertheless,thecombinationgrouptendedtohaveagreaterreductioninCRT(WMD,-4.13μm;95%CI,-25.88to17.63,P=0.71).Theproportionofpatientsgainingmorethan3linesatmonth12intheranibizumabgroupwashigherthaninthecombinationgroupandtherewasasignificantdifference(RR,0.72;95%CI,0.54to0.95;P=0.02).Whereastherewasnosignificantdifferencefortheproportionofpatientsgainingmorethan0lineatmonth12betweenthetwogroups(RR,0.93;95%CI,0.76to1.15;P=0.52).Thegeneraltendencyshowsareductioninranibizumabretreatmentnumberinthecombinationtreatmentgroupcomparedwiththeranibizumabmonotherapygroup.Asmajoradverseevents,thedifferencesinthenumberofeyepain,endophthalmitis,hypertensionandarterialt